慢性免疫介导周围神经病的免疫治疗进展
The Progress of Immunotherapy for Chronic Immune-Mediated Peripheral Neuropathy
摘要: 慢性免疫介导周围神经病是一组由免疫系统调节功能紊乱导致的、以慢性进行性或复发性病程为特征的周围神经疾病,主要包括慢性炎性脱髓鞘性多发性神经根神经病、多灶性运动神经病、抗髓鞘相关糖蛋白抗体相关神经病以及自身免疫性郎飞结病。传统的一线治疗(糖皮质激素、静脉注射免疫球蛋白和血浆置换)虽能使多数患者获益,但仍有约20%~30%的患者疗效不佳、易复发或难以耐受长期治疗。近年来,随着对疾病免疫病理机制认识的深化,靶向B细胞、新生儿Fc受体、补体系统及细胞内信号通路的治疗策略取得了突破性进展,为难治性患者提供了新的选择。本文旨在系统综述慢性免疫介导周围神经病的新型免疫治疗进展,探讨其作用机制、临床证据及未来发展方向,以期为临床实践提供参考。
Abstract: Chronic immune-mediated peripheral neuropathies are a group of peripheral nerve disorders characterized by chronic progressive or relapsing courses, resulting from dysregulation of the immune system. They mainly include chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, anti-myelin-associated glycoprotein antibody-related neuropathy, and autoimmune nodopathies. Although conventional first-line therapies (glucocorticoids, intravenous immunoglobulin, and plasma exchange) benefit most patients, approximately 20%~30% of patients still show poor response, experience relapses, or have difficulty tolerating long-term treatment. In recent years, with a deeper understanding of the immunopathological mechanisms underlying these diseases, breakthrough progress has been made in therapeutic strategies targeting B cells, the neonatal Fc receptor, the complement system, and intracellular signaling pathways, offering new options for refractory patients. This article aims to systematically review the advances in novel immunotherapies for chronic immune-mediated peripheral neuropathies, discuss their mechanisms of action, clinical evidence, and future directions, with the goal of providing a reference for clinical practice.
文章引用:孙晓瑞, 邸伟. 慢性免疫介导周围神经病的免疫治疗进展[J]. 临床医学进展, 2026, 16(4): 3960-3967. https://doi.org/10.12677/acm.2026.1641664

参考文献

[1] Shastri, A., Al Aiyan, A., Kishore, U. and Farrugia, M.E. (2023) Immune-Mediated Neuropathies: Pathophysiology and Management. International Journal of Molecular Sciences, 24, Article No. 7288. [Google Scholar] [CrossRef] [PubMed]
[2] Rajabally, Y. (2024) Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks. ImmunoTargets and Therapy, 13, 99-110. [Google Scholar] [CrossRef] [PubMed]
[3] Briani, C. and Visentin, A. (2026) Immunotherapies in Chronic Immune-Mediated Neuropathies. In: Handbook of Clinical Neurology, Elsevier, 345-356. [Google Scholar] [CrossRef
[4] Oaklander, A.L., Lunn, M.P., Hughes, R.A., van Schaik, I.N., Frost, C. and Chalk, C.H. (2017) Treatments for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): An Overview of Systematic Reviews. Cochrane Database of Systematic Reviews, 2017, CD010369. [Google Scholar] [CrossRef] [PubMed]
[5] Kiers, L. and Cruse, B. (2025) Evaluation and Treatment of Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy. BMJ Neurology Open, 7, e001318. [Google Scholar] [CrossRef
[6] Min, Y.G., Visentin, A., Briani, C. and Rajabally, Y.A. (2025) Neuropathy with Anti-Myelin-Associated Glycoprotein Antibodies: Update on Diagnosis, Pathophysiology and Management. Journal of Neurology, Neurosurgery & Psychiatry, 96, 340-349. [Google Scholar] [CrossRef] [PubMed]
[7] Van den Bergh, P.Y.K., van Doorn, P.A., Hadden, R.D.M., Avau, B., Vankrunkelsven, P., Allen, J.A., et al. (2021) European Academy of Neurology/Peripheral Nerve Society Guideline on Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Report of a Joint Task Force—Second Revision. European Journal of Neurology, 28, 3556-3583. [Google Scholar] [CrossRef] [PubMed]
[8] Kuwabara, S. (2024) Typical CIDP: Update of the Pathogenesis, Diagnosis, and Treatment. Brain and Nerve, 76, 515-519. [Google Scholar] [CrossRef] [PubMed]
[9] 中华医学会神经病学分会, 中华医学会神经病学分会周围神经病协作组, 中华医学会神经病学分会肌电图与临床神经电生理学组, 中华医学会神经病学分会神经肌肉病学组. 慢性炎性脱髓鞘性多发性神经根神经病诊治中国专家共识2022 [J]. 中华神经科杂志, 2023, 56(2): 125-132.
[10] Muley, S.A., Jacobsen, B., Parry, G., Usman, U., Ortega, E., Walk, D., et al. (2020) Rituximab in Refractory Chronic Inflammatory Demyelinating Polyneuropathy. Muscle & Nerve, 61, 575-579. [Google Scholar] [CrossRef] [PubMed]
[11] Benedetti, L., Briani, C., Franciotta, D., Fazio, R., Paolasso, I., Comi, C., et al. (2011) Rituximab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Report of 13 Cases and Review of the Literature. Journal of Neurology, Neurosurgery & Psychiatry, 82, 306-308. [Google Scholar] [CrossRef] [PubMed]
[12] Doneddu, P.E., Cocito, D., Fazio, R., Benedetti, L., Peci, E., Liberatore, G., et al. (2024) Prospective Open-Label Trial with Rituximab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy Not Responding to Conventional Immune Therapies. Journal of Neurology, Neurosurgery & Psychiatry, 95, 838-844. [Google Scholar] [CrossRef] [PubMed]
[13] Du, Y., Yan, Q., Li, C., Zhu, W., Zhao, C., Hao, Y., et al. (2024) Efficacy and Safety of Combined Low‐Dose Rituximab Regimen for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Annals of Clinical and Translational Neurology, 12, 180-191. [Google Scholar] [CrossRef] [PubMed]
[14] Nobile-Orazio, E., Cocito, D., Manganelli, F., Fazio, R., Lauria Pinter, G., Benedetti, L., et al. (2025) Rituximab versus Placebo for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Randomized Trial. Brain, 148, 1112-1121. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, J. and Xiang, Q. (2024) Successful Treatment of Relapsed and Refractory CIDP with Ofatumumab: A First Case Report. Frontiers in Immunology, 15, Article ID: 1437848. [Google Scholar] [CrossRef] [PubMed]
[16] Casertano, S., Signoriello, E., Rossi, F., Di Pietro, A., Tuccillo, F., Bonavita, S., et al. (2020) Ocrelizumab in a Case of Refractory Chronic Inflammatory Demyelinating Polyneuropathy with Anti‐Rituximab Antibodies. European Journal of Neurology, 27, 2673-2675. [Google Scholar] [CrossRef] [PubMed]
[17] Dalakas, M.C. and Spaeth, P.J. (2021) The Importance of FcRn in Neuro-Immunotherapies: From IgG Catabolism, fcgrt Gene Polymorphisms, IVIg Dosing and Efficiency to Specific FcRn Inhibitors. Therapeutic Advances in Neurological Disorders, 14. [Google Scholar] [CrossRef] [PubMed]
[18] Allen, J.A., Lin, J., Basta, I., Dysgaard, T., Eggers, C., Guptill, J.T., et al. (2024) Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (ADHERE): A Multicentre, Randomised-Withdrawal, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet Neurology, 23, 1013-1024. [Google Scholar] [CrossRef] [PubMed]
[19] Levine, T. and Muley, S. (2025) Early Deterioration of CIDP Following Transition from IVIG to FcRn Inhibitor Treatment. Journal of the Neurological Sciences, 468, Article ID: 123313. [Google Scholar] [CrossRef] [PubMed]
[20] Querol, L., De Sèze, J., Dysgaard, T., Levine, T., Rao, T.H., Rivner, M., et al. (2024) Efficacy, Safety and Tolerability of Rozanolixizumab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Randomised, Subject-Blind, Investigator-Blind, Placebo-Controlled, Phase 2a Trial and Open-Label Extension Study. Journal of Neurology, Neurosurgery & Psychiatry, 95, 845-854. [Google Scholar] [CrossRef] [PubMed]
[21] Querol, L.A., Hartung, H., Lewis, R.A., van Doorn, P.A., Hammond, T.R., Atassi, N., et al. (2022) The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics, 19, 864-873. [Google Scholar] [CrossRef] [PubMed]
[22] Querol, L., Lewis, R.A., Hartung, H., Van Doorn, P.A., Wallstroem, E., Luo, X., et al. (2023) An Innovative Phase 2 Proof‐of‐Concept Trial Design to Evaluate SAR445088, a Monoclonal Antibody Targeting Complement C1s in Chronic Inflammatory Demyelinating Polyneuropathy. Journal of the Peripheral Nervous System, 28, 276-285. [Google Scholar] [CrossRef] [PubMed]
[23] Mevorach, D., Reiner, I., Grau, A., Ilan, U., Berkun, Y., Ta‐Shma, A., et al. (2016) Therapy with Eculizumab for Patients with CD59 P.cys89tyr Mutation. Annals of Neurology, 80, 708-717. [Google Scholar] [CrossRef] [PubMed]
[24] Pitarokoili, K., Yoon, M., Kröger, I., Reinacher-Schick, A., Gold, R. and Schneider-Gold, C. (2017) Severe Refractory CIDP: A Case Series of 10 Patients Treated with Bortezomib. Journal of Neurology, 264, 2010-2020. [Google Scholar] [CrossRef] [PubMed]
[25] Burt, R.K., Balabanov, R., Tavee, J., Han, X., Sufit, R., Ajroud-Driss, S., et al. (2020) Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Journal of Neurology, 267, 3378-3391. [Google Scholar] [CrossRef] [PubMed]
[26] Zheng, Y., Hu, J., Sun, C., Zhao, C. and Lin, J. (2023) Efficacy of Hematopoietic Stem Cell Transplantation Treatment in Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta‐Analysis. European Journal of Neurology, 30, 2570-2582. [Google Scholar] [CrossRef] [PubMed]
[27] Dong, M., Mei, Z., Zhou, L., Heming, M., Xu, L., Liu, Y., et al. (2025) Anti-bcma CAR-T Cell Therapy in Relapsed/Refractory Chronic Inflammatory Demyelinating Polyneuropathy. Med, 6, Article ID: 100704. [Google Scholar] [CrossRef] [PubMed]
[28] Claytor, B., Polston, D. and Li, Y. (2025) Multifocal Motor Neuropathy: A Narrative Review. Muscle & Nerve, 71, 512-534. [Google Scholar] [CrossRef] [PubMed]
[29] Keddie, S., Eftimov, F., van den Berg, L.H., Brassington, R., de Haan, R.J. and van Schaik, I.N. (2022) Immunoglobulin for Multifocal Motor Neuropathy. Cochrane Database of Systematic Reviews, 2022, CD004429. [Google Scholar] [CrossRef] [PubMed]
[30] Sharawat, I.K., Panda, P., Dawman, L., Kasinathan, A. and Panda, P.K. (2025) Efficacy of Subcutaneous and Intravenous Immunoglobulin in Patients with Multifocal Motor Neuropathy: A Systematic Review and Meta-Analysis. Annals of Indian Academy of Neurology, 28, 485-494. [Google Scholar] [CrossRef] [PubMed]
[31] Al-Zuhairy, A., Sindrup, S.H. and Jakobsen, J. (2021) Long-Term Follow-Up of Facilitated Subcutaneous Immunoglobulin Therapy in Multifocal Motor Neuropathy. Journal of the Neurological Sciences, 427, Article ID: 117495. [Google Scholar] [CrossRef] [PubMed]
[32] Pestronk, A. (2003) Treatment of IgM Antibody Associated Polyneuropathies Using Rituximab. Journal of Neurology, Neurosurgery & Psychiatry, 74, 485-489. [Google Scholar] [CrossRef] [PubMed]
[33] Chaganti, S., Hannaford, A. and Vucic, S. (2022) Rituximab in Chronic Immune Mediated Neuropathies: A Systematic Review. Neuromuscular Disorders, 32, 621-627. [Google Scholar] [CrossRef] [PubMed]
[34] Budding, K., Johansen, L.E., Van de Walle, I., Dijkxhoorn, K., de Zeeuw, E., Bloemenkamp, L.M., et al. (2022) Anti-c2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy. Neurology Neuroimmunology & Neuroinflammation, 9, e1107. [Google Scholar] [CrossRef] [PubMed]
[35] Fitzpatrick, A.M., Mann, C.A., Barry, S., Brennan, K., Overell, J.R. and Willison, H.J. (2011) An Open Label Clinical Trial of Complement Inhibition in Multifocal Motor Neuropathy. Journal of the Peripheral Nervous System, 16, 84-91. [Google Scholar] [CrossRef] [PubMed]
[36] Lunn, M.P. and Nobile-Orazio, E. (2016) Immunotherapy for IgM Anti-Myelin-Associated Glycoprotein Paraprotein-Associated Peripheral Neuropathies. Cochrane Database of Systematic Reviews, 2016, CD002827. [Google Scholar] [CrossRef] [PubMed]
[37] Léger, J., Viala, K., Nicolas, G., Créange, A., Vallat, J., Pouget, J., et al. (2013) Placebo-Controlled Trial of Rituximab in IgM Anti-Myelin-Associated Glycoprotein Neuropathy. Neurology, 80, 2217-2225. [Google Scholar] [CrossRef] [PubMed]
[38] Tang, M.H., Mathis, S., Duffau, P., Cazenave, P., Solé, G., Duval, F., et al. (2020) Prognostic Factor of Poor Outcome in Anti-MAG Neuropathy: Clinical and Electrophysiological Analysis of a French Cohort. Journal of Neurology, 267, 561-571. [Google Scholar] [CrossRef] [PubMed]
[39] Parisi, M., Dogliotti, I., Clerico, M., Bertuzzo, D., Benevolo, G., Orsucci, L., et al. (2022) Efficacy of Rituximab in Anti‐Myelin‐Associated Glycoprotein Demyelinating Polyneuropathy: Clinical, Hematological and Neurophysiological Correlations during 2 Years of Follow‐Up. European Journal of Neurology, 29, 3611-3622. [Google Scholar] [CrossRef] [PubMed]
[40] Castellani, F., Visentin, A., Schirinzi, E., Salvalaggio, A., Cacciavillani, M., Candiotto, C., et al. (2023) Mutational Profile in 75 Patients with Anti-Myelin-Associated Glycoprotein Neuropathy. Neurology Neuroimmunology & Neuroinflammation, 10, e200122. [Google Scholar] [CrossRef] [PubMed]
[41] Castellani, F., Visentin, A., Campagnolo, M., Salvalaggio, A., Cacciavillani, M., Candiotto, C., et al. (2020) The Bruton Tyrosine Kinase Inhibitor Ibrutinib Improves Anti-Mag Antibody Polyneuropathy. Neurology Neuroimmunology & Neuroinflammation, 7, e720. [Google Scholar] [CrossRef] [PubMed]
[42] Querol, L. and Dalakas, M.C. (2025) The Discovery of Autoimmune Nodopathies and the Impact of IgG4 Antibodies in Autoimmune Neurology. Neurology Neuroimmunology & Neuroinflammation, 12, e200365. [Google Scholar] [CrossRef] [PubMed]
[43] Liu, B., Hu, J., Sun, C., Qiao, K., Xi, J., Zheng, Y., et al. (2023) Effectiveness and Safety of Rituximab in Autoimmune Nodopathy: A Single-Center Cohort Study. Journal of Neurology, 270, 4288-4295. [Google Scholar] [CrossRef] [PubMed]
[44] Tao, Z., Jiang, Y., Gui, Q. and Ma, J. (2026) Efficacy and Safety of Anti-CD20 Monoclonal Antibody Therapy for Autoimmune Nodopathies: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 17, Article ID: 1759210. [Google Scholar] [CrossRef
[45] Scheibe, F., Ostendorf, L., Prüss, H., Radbruch, H., Aschman, T., Hoffmann, S., et al. (2022) Daratumumab for Treatment‐Refractory Antibody‐Mediated Diseases in Neurology. European Journal of Neurology, 29, 1847-1854. [Google Scholar] [CrossRef] [PubMed]